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Objectives: Bone mineral density (BMD) and fragility fracture (FF) have high heritability, but few data
exist on impact of other factors on families with fracture history. We aimed to evaluate predictors of FF
and low BMD, in patients with family history of FF.
Methods: This was a retrospective study on patients undergoing dual energy X-ray absorptiometry at a
district general hospital (DGH), 2004e2016. Parameters recorded (in addition to standard dual energy X-
ray absorptiometry parameters): age, smoking, alcohol, corticosteroids, aromatase inhibitors, Depo-
Provera, hormone replacement therapy, rheumatoid arthritis, polymyalgia rheumatica, breast or pros-
tate cancer, coeliac disease, and fracture site. Logistic regression was used to model fracture risk and site,
and linear regression for impact of factors on L1e4 and femoral BMD. Factor analyses with polychoric
correlation matrices and calculation of Eigenvalues were applied to determine association between
fracture sites and associated risk factors.
Results: A total of 6053 patients were included, 91.1% female. 2094 had sustained at least one FF.
Smoking, alcoholism, increased age, height, and fat mass increased FF risk. Sites analysed: femur, tibia/
ﬁbula, humerus, forearm, ribs, and vertebrae. Alcoholism, and increasing tissue thickness and fat mass
signiﬁcantly increased FF risk. Decreased right femoral and vertebral BMD increased overall FF risk.
Conclusions: Our study conﬁrms the effect of certain factors on vertebral BMD, but suggests a differential
effect on the upper and lower spine, as well as in the dominant and nondominant hip. Different sites of
fracture are associated with different risk factors, the most common sites of fracture being the peripheral
long bones and vertebrae.
© 2019 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fragility fractures (FF) are fractures due to low level (‘low en-
ergy’) force, deﬁned by the World Health Organisation (WHO) as
forces equivalent to a fall from standing height or less. Factors
known to predispose to FF in the general population include
reduced bonemineral density (BMD), systemic corticosteroids [1,2],
increasing age, female gender, previous fractures [3,4], menopause
[5], and family history of osteoporosis [6]. In the UK, over 300,000
patients present with FF to hospital each year [7]. These cause
signiﬁcant morbidity and disability, and can lead to decreasedrecambe Bay NHS Foundation
n Road, Lancaster, Lancashire,
ociety of Osteoporosis.
osis. Publishing services by Elsevquality of life and even death [8]. They most commonly occur in the
vertebrae, proximal femur and distal radius, and less commonly in
the humerus, pelvis, ribs and other bones.
Bone loss increases with age in both men and women, due to
age-related factors, and menopause in women, leading to osteo-
porosis. This is deﬁned as low bone mass with structural loss of
bone tissue, increasing susceptibility to FF. The global trend to-
wards an ageing population means the incidence of both osteo-
porosis and FF is likely to increase. Hip fractures alone are expected
to increase in incidence from 91,500 in 2015 to 101,000 in 2020 [7].
While low BMD is an important risk factor for FF, it is important
to note that more than half of postmenopausal women sustaining
such a fracture do not have osteoporosis [9]. This makes the
assessment of other skeletal and nonskeletal factors of clinical
importance when assessing fracture risk, as acknowledged by tools
such as Fracture Risk Assessment Tool (FRAX®), themost commonly
used predictor worldwide.
FRAX® and similar tools provide a 10-year risk of majorier B.V. This is an open access article under the CC BY-NC-ND license (http://
Table 2
Factors predicting fracture risk.
Predictor OR (95% CI)
Smoking (n¼ 767) 1.158 (0.985e1.360)
Alcohol excess (n¼ 357) 1.263 (1.012e1.571)
Rheumatoid arthritis (n¼ 311) 1.068 (0.840e1.352)
Polymyalgia rheumatic (n¼ 104) 1.001 (0.660e1.494)
Depo-Provera (n¼ 73) 1.038 (0.480e2.133)
Coeliac disease (n¼ 157) 0.575 (0.391e0.826)
History of breast/prostate cancer (n¼ 77) 0.803 (0.483e1.295)
Female gender (n¼ 5513) 0.946 (0.788e1.140)
Hormone replacement therapy (n¼ 388) 0.586 (0.459e0.741)
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considered when calculating fracture risk is a family history of FF.
While several studies have demonstrated the heritability of BMD,
and an increased risk of FF in those with a parental history of
fracture, independent of BMD, few studies have analysed the effect
of other factors in this cohort of patients [6,10]. Additionally, most
studies focus on the risk of hip fracture, with little data available on
the impact of various factors on FF at other sites, in patients with a
history of parental fracture. As outlined above, osteoporosis and
associated fractures carry signiﬁcant morbidity andmortality in the
general population. Given the high level of heritability of osteo-
porosis and decreased BMD, it is important to determine the
multiple factors that inﬂuence fracture risk in those with a family
history of FF.
We set out to analyse predictors of FF and low BMD in patients
with a history of parental fracture, presenting for dual energy X-ray
absorptiometry (DEXA). Additionally, we analysed predictors of site
of fracture and associations between sites.
2. Methods
Patients with a history of parental FF, referred for DEXA scanning
at a DGH between 2004 and 2016, were included in the study. DEXA
machine and parameters were appropriately calibrated prior to
measurement. Parameters recorded were: femoral BMD, vertebral
BMD, height, weight, fat mass, leanmass. Additionally, the following
factors were recorded: age at scan, history of fracture, smoking
status, alcohol consumption, history of corticosteroid therapy, his-
tory of aromatase inhibitor therapy, Depo-Provera use, hormone
replacement therapy (HRT), history of rheumatoid arthritis (RA),
history of polymyalgia rheumatica (PMR), history of breast or
prostate cancer, and coeliac disease. For patients with a history of
fracture, site of fracture was recorded. Fracture sites recorded were
as follows: forearm, tibia or ﬁbula, humerus, femur, ribs, vertebrae.
The statistical software ‘R’ was used for data analysis. Logistic
regression was used to model fracture risk and site of FF, compared
to all other FF in the cohort using the above risk factors. The model
was adjusted for corticosteroid use due to being a potential
confounder for increased risk of fracture. Linear regression was
used to model the impact of each of the above factors on BMD at
L1e4, femoral neck, and total BMD. Factor analyses with polychoric
correlation matrices were applied to determine association be-
tween fracture sites. Any associations with Eigenvalues of more
than one were then examined using a logistic model to analyse the
effect of the above risk factors. Appropriate ethics approval was
obtained for this project, in linewith the principles embodied in the
Declaration of Helsinki. The study was approved by the NorthWest
(UK) ethics committee (IRB ethics approval: 14/NW/1136). Consent
has been obtained from each patient or subject after full explana-
tion of the purpose and nature of all procedures used.
3. Results
A total of 6053 patients were included in the study, 5513 (91.1%)
female. 2094 (34.6%) had sustained at least one FF. Table 1Table 1
Summary of continuous variables.
Parameter Mean± SD
Height, cm 162.10± 7.59
Weight, kg 69.46± 15.56
Average percentage fat, % 0.29± 0.07
Average tissue thickness, cm 15.51± 2.10
Age at scan, yr 60.59± 11.20
SD, standard deviation.summarises the continuous variables used to predict fracture risk
in the subsequent tables. Table 2 shows the effect of factors on
fracture risk and BMD, adjusted for corticosteroid use. Overall,
alcoholism (odds ratio [OR], 1.263; 95% conﬁdence interval [CI],
1.012e1.571), and increasing tissue thickness (OR, 1.017; 95% CI,
1.008e1.026) and fat mass (OR, 6.571; 95% CI, 4.877e8.859)
signiﬁcantly increased FF risk (Table 2). HRT, aromatase inhibitor
use, and coeliac disease were found to be protective for FF in this
cohort.
Table 3 shows the effect of factors on BMD at the vertebrae and
the left and right femur (total and neck only).
A history of breast or prostate cancer, female sex, and increased
age signiﬁcantly decreased vertebral BMD, both at L1e2 and L1e4.
There was a differential effect of various factors on right and left
femoral BMD, as well as variation according to speciﬁc femoral
sites. RA, female, and increased age also decreased right femoral
BMD; however, left femoral BMD was signiﬁcantly decreased by
none of the factors included in this study.
Table 4 shows factors affecting FF risk at various sites. Sites
analysed were: femur, tibia or ﬁbula, humerus, forearm, ribs, and
spine. Increased age conferred increased fracture risk at all sites.
Increased percentage fact signiﬁcantly increased fracture risk at all
sites except the ribs, with the most signiﬁcant effect demonstrated
in the tibia and ﬁbula. In the peripheral long bones (i.e., forearm
and tibia/ﬁbula), fracture risk was signiﬁcantly increased by female
sex, increasing age and increasing percentage fat. RA only increased
fracture risk in the femur. The risk of sustaining rib fracture was
increased by smoking and alcoholism.
Several factors were found to be protective against FF, as sum-
marised in Tables 3 and 4. Depo-Provera use reduced fracture risk in
the vertebrae; coeliac disease reduced fracture risk in the forearm
and vertebrae; HRT reduced fracture risk in the forearm, humerus,
and vertebrae; aromatase inhibitors reduced fracture risk in all arm
bones, tibia and ﬁbula, and vertebrae. Increased height reduced
fracture risk throughout the arm and vertebrae, while increased
weight reduced fracture risk at all sites except the tibia, ﬁbula, and
vertebrae. Increased percentage fat protected against rib fractures.
Female gender conferred reduced risk of fracture in the femur, ribs,
and vertebrae. Increased BMD in the right femur and L1e2 conferred
reduced risk of fracture at all sites except the tibia and ﬁbula.
Polychoric correlation matrices were applied to determine as-
sociation between fracture sites. Fracture sites with Eigenvalue ofAromatase inhibitors (n¼ 424) 0.489 (0.383e0.618)
Age at scan, yr 1.012 (0.100e1.026)
Height, cm 0.984 (0.980e0.987)
Weight, kg 0.100 (0.998e1.001)
Average percentage fat, % 6.571 (4.877e8.859)
Average tissue thickness, cm 1.017 (1.008e1.026)
BMD- L1e2, g/cm2 0.113 (0.082e0.155)
BMD- L1e4, g/cm2 0.122 (0.090e0.164)
BMD- Left femoral total, g/cm2 0.016 (<0.001e1.589)
BMD- Right femoral total, g/cm2 0.041 (0.027e0.062)
OR, odds ratio; CI, conﬁdence interval; BMD, bone mineral density.
Table 3
Factors affecting bone mineral density in vertebrae and femur (total and neck).
Variable L1e2 L1e4 Left femur- total Left femur- neck Right femur- total Right femur- neck
Smoking 1.006 (1.000e1.013) 1.004 (0.997e1.011) 0.986 (0.919e1.059) 1.034 (0.975e1.098) 0.997 (0.992e1.002) 0.999 (0.994e1.004)
Alcohol 1.014 (1.005e1.023) 1.005 (0.996e1.015) 1.195 (1.011e1.413) 1.148 (1.009e1.307) 1.004 (0.997e1.013) 1.006 (0.999e1.014)
RA 1.000 (0.983e1.018) 1.020 (1.001e1.040) 0.897 (0.755e1.067) 0.988 (0.844e1.156) 0.975 (0.960e0.990) 0.981 (0.967e0.995)
PMR 1.038 (1.007e1.071) 1.065 (1.031e1.100) 0.942 (0.700e1.269) 0.914 (0.703e1.189) 1.028 (1.001e1.057) 0.991 (0.966e1.016)
Depo-Provera 1.043 (1.017e1.070) 1.037 (1.010e1.065) 0.893 (0.773e1.033) NA 1.043 (1.022e1.066) 1.044 (1.022e1.065)
Coeliac disease 0.996 (0.970e1.022) 0.983 (0.957e1.011) 0.879 (0.741e1.044) 0.960 (0.794e1.160) 1.003 (0.982e1.024) 1.016 (0.996e1.037)
History of breast/prostate
cancer
0.944 (0.912e0.977) 0.950 (0.917e0.984) 1.001 (0.743e1.349) 0.994 (0.763e1.295) 0.978 (0.950e1.006) 0.982 (0.956e1.008)
Female sex 0.929 (0.914e0.944) 0.932 (0.916e0.948) 0.951 (0.837e1.081) 0.933 (0.847e1.028) 0.931 (0.918e0.944) 0.945 (0.933e0.957)
HRT 1.046 (1.027e1.064) 1.062 (1.043e1.081) 1.112 (0.827e1.496) 1.107 (0.918e1.334) 1.036 (1.021e1.051) 1.039 (1.025e1.055)
Aromatase inhibitors 1.012 (1.005e1.020) 1.013 (1.005e1.021) 0.998 (0.929e1.073) 0.987 (0.908e1.073) 1.012 (1.006e1.019) 1.005 (0.998e1.011)
Age at scan 0.996 (0.996e0.996) 0.997 (0.996e0.997) 0.999 (0.995e1.003) 0.995 (0.992e0.998) 0.995 (0.995e0.996) 0.995 (0.995e0.995)
Height 1.005 (1.004e1.006) 1.005 (1.004e1.006) 1.004 (0.998e1.011) 1.006 (1.001e1.010) 1.004 (1.004e1.005) 1.006 (1.005e1.006)
Weight 1.004 (1.004e1.005) 1.005 (1.004e1.005) 1.006 (1.004e1.008) 1.003 (1.001e1.006) 1.004 (1.004e1.005) 1.004 (1.003e1.004)
Average percentage fat 1.540 (1.483e1.600) 1.530 (1.470e1.592) 1.556 (0.880e2.751) 0.836 (0.499e1.400) 1.091 (1.032e1.154) 0.976 (0.927e1.028)
Average tissue thickness 1.017 (1.016e1.019) 1.018 (1.016e1.019) 1.033 (1.019e1.047) 1.014 (0.998e1.029) 1.030 (1.028e1.031) 1.022 (1.020e1.023)
Values are presented as odds ratio (95% conﬁdence interval).
RA, rheumatoid arthritis; PMR, polymyalgia rheumatic; HRT, hormone replacement therapy; NA, not applicable.
Table 4
Factors affecting fracture site.
Predictor Fracture site
Forearm (n¼ 1002) Tibia/ﬁbula (n¼ 544) Humerus (n¼ 235) Femur (n¼ 157) Ribs (n¼ 272) Vertebrae (n¼ 394)
Smoking 0.921 (0.741e1.137) 1.318 (1.021e1.686) 1.219 (0.819e1.764) 1.416 (0.877e2.203) 1.769 (1.264e2.437) 1.119 (0.813e1.514)
Alcohol 1.154 (0.869e1.512) 0.983 (0.660e1.414) 1.594 (0.976e2.470) 1.378 (0.717e2.407) 1.649 (1.042e2.495) 1.296 (0.850e1.901)
A 1.038 (0.758e1.394) 0.920 (0.596e1.361) 1.564 (0.922e2.495) 2.314 (1.333e3.771) 0.770 (0.392e1.356) 1.515 (0.999e2.215)
PMR 1.281 (0.770e2.037) 1.328 (0.687e2.343) 0.732 (0.179e1.963) 1.118 (0.273e3.013) 0.622 (0.154e1.680) 1.037 (0.434e2.091)
Depo-Provera 2.079 (0.906e4.386) 0.699 (0.113e2.328) <0.001 (<0.001e1.626) <0.001 (<0.001
e>1000)
0.712 (0.040e3.339) <0.001 (<0.001
e0.942)
Coeliac disease 0.605 (0.351e0.977) 0.609 (0.287e1.133) 0.476 (0.117e1.265) 0.236 (0.013e1.061) 0.841 (0.328e1.759) 0.369 (0.113e0.878)
History of breast/prostate
cancer
0.750 (0.361e1.395) 0.700 (0.245e1.575) 0.657 (0.108e2.104) 0.491 (0.028e2.233) 0.564 (0.092e1.802) 0.579 (0.141e1.560)
Female sex 2.311 (1.709e3.202) 1.421 (1.016e2.050) 1.267 (0.791e2.170) 0.401 (0.270e0.613) 0.671 (0.470e0.989) 0.388 (0.298e0.511)
HRT 0.546 (0.383e0.755) 0.905 (0.612e1.293) 0.438 (0.186e0.867) 0.473 (0.167e1.045) 0.785 (0.433e1.307) 0.521 (0.288e0.863)
Aromatase inhibitors 0.448 (0.311e0.625) 0.486 (0.298e0.748) 0.402 (0.170e0.795) 0.810 (0.381e1.510) 0.711 (0.393e1.183) 0.617 (0.367e0.971)
Age at scan 1.030 (1.027e1.033) 1.019 (1.015e1.023) 1.043 (1.037e1.049) 1.056 (1.048e1.065) 1.008 (1.003e1.012) 1.052 (1.048e1.057)
Height 0.977 (0.973e0.982) 0.998 (0.993e1.004) 0.979 (0.971e0.987) 1.001 (0.990e1.013) 1.003 (0.996e1.010) 0.972 (0.966e0.978)
Weight 0.997 (0.996e0.999) 1.012 (1.010e1.015) 0.994 (0.990e0.998) 0.991 (0.985e0.997) 0.981 (0.977e0.985) 0.997 (0.994e0.100)
Average percentage fat 3.921 (2.710e5.676) 19.619 (12.078
e31.901)
8.365 (4.176e16.758) 2.251 (0.831e6.099) 0.146 (0.078e0.272) 4.613 (2.734e7.789)
BMD- L1e2 0.082 (0.054e0.122) 0.724 (0.447e1.166) 0.169 (0.082e0.343) 0.311 (0.126e0.751) 0.060 (0.030e0.119) 0.162 (0.093e0.282)
BMD- L1e4 0.089 (0.060e0.130) 0.664 (0.418e1.046) 0.140 (0.069e0.281) 0.505 (0.212e1.174) 0.055 (0.028e0.107) 0.127 (0.074e0.215)
BMD- Left femoral total 0.003 (<0.001e0.852) 0.267 (0.0002
e178.120)
0.889 (0.0001
e3070.715)
253.2 (<0.001
e>1000)
145.1 (<0.001
e>1000)
0.007 (<0.001
e>1000)
BMD- Left femoral neck 0.427 (0.0005
e230.984)
0.007 (<0.001
e10.611)
5.144 (<0.001e>1000) 36.651 (<0.001
e>1000)
>1000 (696.5
e>1000)
1.912 (<0.001
e>1000)
BMD- Right femoral total 0.043 (0.026e0.072) 0.678 (0.367e1.246) 0.023 (0.009e0.061) 0.002 (0.0002e0.021) 0.033 (0.014e0.078) 0.042 (0.020e0.085)
BMD- Right femoral neck 0.028 (0.016e0.049) 0.567 (0.291e1.095) 0.032 (0.011e0.092) 0.001 (0.0001e0.016) 0.056 (0.022e0.143) 0.018 (0.008e0.041)
Values are presented as odds ratio (95% conﬁdence interval).
RA, rheumatoid arthritis; PMR, polymyalgia rheumatic; HRT, hormone replacement therapy; BMD, bone mineral density.
Table 5
Age-adjusted predictors of fracture for tibia/ﬁbula/vertebrae/ribs vs. hu-
merus/forearm/femur.
Variable OR (95% CI)
Smoking 0.879 (0.779e0.992)
Alcohol 0.954 (0.808e1.127)
RA 1.393 (0.928e2.092)
PMR 0.907 (0.465e1.769)
HRT 0.635 (0.420e0.961)
Aromatase inhibitors 0.950 (0.772e1.170)
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with least covariability (humerus, forearm, femur) (Table 5). These
2 cohorts were signiﬁcantly different in age; therefore, an age-
adjusted model was applied. Smoking (OR, 0.879; 95% CI,
0.779e0.992) and HRT (OR, 0.635; 95% CI, 0.420e0.961) signiﬁ-
cantly impacted clustering of fractures in the tibia/ﬁbula, vertebrae,
ribs, compared with clustering at the humerus, forearm, and femur.
Smoking and HRT were found to protect against fractures in the
ﬁrst cluster (tibia or ﬁbula, vertebrae, and ribs), when compared
with the second cluster.Breast/prostate cancer 1.489 (0.610e3.636)
Female sex 0.804 (0.589e1.096)
Age at scan, yr 1.011 (1.003e1.019)
Height, cm 0.989 (0.978e1.000)
Weight, kg 0.995 (0.989e1.000)
OR, odds ratio; CI, conﬁdence interval; RA, rheumatoid arthritis; PMR,
polymyalgia rheumatic; HRT, hormone replacement therapy.4. Discussion
4.1. Summary
In this retrospective study on patients with a family history of
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dictors of FF overall. Risk factors for decreased BMD, and risk of
fracture, were found to differ between the dominant and
nondominant hip. In the presence of pre-existing rheumatological
disease, RA signiﬁcantly decreased right femoral BMD and
increased fracture risk in the femur. The most common sites of
fracture in this cohort were the peripheral long bones and verte-
brae, with signiﬁcant clustering seen in fractures of the tibia/ﬁbula,
vertebrae, and ribs.
4.2. Strengths and limitations
Key strengths of this study include the large sample size,
duration overwhich datawas collected, and range of characteristics
recorded. We have not only evaluated fracture risk at individual
sites, but also association between sites. The population studied is
largely homogeneous, with little turnover or variation, strength-
ening comparative analyses. Limitations of this study include the
lack of data on dose and duration of all drugs, including total cu-
mulative dose of corticosteroids. Levels of smoking and alcohol
consumptions were not deﬁned within the dataset. Certain clinical
factors were also not known, such as proportion of women who
were postmenopausal at time of fracture and/or DEXA, as well as
fall propensity. Data on treatment for osteoporosis in this cohort
was not available, including bisphosphonate treatment, or vitamin
D and calcium replacement.
With regards family history, it was not known which parent
sustained a fracture. It was also not known at what age parents
sustained a FF, or at which anatomical site. This is an important
limitation, as genetic factors are believed to be strong determinants
of offspring site of fracture and age [11,12]. In the absence of this
data, we were thus unable to perform further sensitivity analyses
which may reveal the potential differential effect between parental
fracture above and below the age of 80 years.
4.3. Predictors of fracture and low bone mineral density
Recent studies show a strong association between parental and
offspring BMD, with peak bone mass acquisition more signiﬁcantly
inﬂuenced by genetic rather than other factors such as lifestyle and
environment. The risk of developing osteoporosis and subsequent
fractures is highly dependent on peak bone mass attained [6,13].
These large cohort studies have conﬁrmed heritability of low BMD,
but until now, little data has existed on fracture risk, the most
important and debilitating complication of the disease.
Similar to studies in the general population, alcohol was found
to increase fracture risk [7]. A differential effect of BMD and fracture
risk in the dominant and nondominant hip was found. RA and
increased age signiﬁcantly decreased right total femoral BMD and
increased femoral fracture risk. These factors conferred no signiﬁ-
cant effect on left femoral BMD. Certain factors signiﬁcantly
increased right femoral BMD, but not the left, including PMR, HRT,
and height. It is not clear as to why there is a differential effect of
risk factors on the fracture risk between the dominant and
nondominant hips, and may have several explanations, related to
the mechanism of injury. One reason may be the mechanism of
mobilisation, with patients more likely to weight-bear on their
dominant limb. The mechanism of falling is also known to play a
key role in the site and severity of subsequent fracture [14]. It is
likely that an individual experiencing a fall, regardless of distance
fallen, will reach out with their dominant arm to steady themselves
as they reach the ground. This will therefore lead to greater impact
on the dominant side, thus leading to a greater likelihood of frac-
tures in limbs on this side, including the hip. This may also lead to
coexistent fractures of the spine, as well as peripheral long bones,including at the wrist, during the fall.
One key limitation of this study is the lack of data on the
treatment of osteoporosis in our cohort. There are comprehensive
guidelines [7] available for the treatment of osteoporosis, the most
commonly prescribed drugs being bisphosphonates such as alen-
dronic acid [15]. Serum levels of vitamin D, or intake of vitamin D
and/or calcium supplementation was also not recorded. This is
important for analysis of our results which show coeliac disease to
be protective for FF, especially in the forearm and vertebrae. Depo-
Provera use and aromatase inhibitors were found to protect against
fracture at certain sites. Coeliac disease is known to slightly in-
crease the risk of FF [16], while aromatase inhibitors signiﬁcantly
increase FF risk, especially in women [17]. Depo-Provera use is also
associated with a slightly increased risk of fracture [18]. The pro-
tective effect seen in the presence of these factors, against FFs, may
be due to commencement of bone protection and/or calcium and
vitamin D in these patients, which paradoxically reduces their
fracture risk. Overall fracture risk was found to be decreased in our
cohort across all risk factors, and this may also be due to treatment
with bone protecting therapies. This limitation may therefore un-
derestimate the risk of FF in our cohort. However, the study pro-
vides further insight into the clustering of fractures, and risk
associated with this.
4.4. Predictors of fracture site
In our cohort, different sites of fracture appear to be associated
with different risk factors. Themost common sites of fracture in this
study were the peripheral long bones and vertebrae, with the fe-
mur being the least common.
Several studies in literature demonstrate the heritability of
fracture risk, more speciﬁcally, in a site-speciﬁc manner. Fractures
of the forearm, especially wrist, have been shown to be particularly
common in terms of heritability, in keeping with the results from
our study [19,20]. Maternal hip fracture has also speciﬁcally been
shown to increase the risk of vertebral fracture, especially in men
[21]. Within an individual, fractures of the spine, humerus, and
pelvis have been demonstrated to increase the risk of further major
osteoporotic fracture within the same individual; however, we
were unable to analyse this in our cohort due to lack of relevant
data [22].
RA signiﬁcantly increases fracture risk in the femur in our cohort
with a family history of FF. This is consistent with results from
studies conducted in the general population, which demonstrate
RA to positively correlatewith increased incidence of vertebral and/
or hip fracture [23,24]. A recent systematic review and meta-
analysis not only conﬁrmed this result, but also conducted site-
speciﬁc analyses in RA patients on fractures in the vertebrae, hip,
forearm, and proximal humerus. Incidence rates were found to be
highest in the vertebrae, leading the authors to suggest vertebral
imaging speciﬁcally in these patients to assess clinical deterioration
of bone structure in the spine, in addition to assessment of other
known osteoporotic risk factors, including those speciﬁc to RA [25].
This is consistent with previous data, demonstrating vertebral
facture rates in RA to be as high as twice the expected value in the
general population [26].
4.5. Association between fracture sites
While there is much pre-existing data on the heritability of FF,
and preferred sites of FF, little data is available on the association
between fracture sites in a given individual. In our cohort of pa-
tients, there was overlap between all fracture sites, with signiﬁcant
clustering seen in fractures of the tibia/ﬁbula, spine, and ribs. After
adjusting for age, smokingwas found to be a signiﬁcant predictor of
M. Dey, M. Bukhari / Osteoporosis and Sarcopenia 5 (2019) 6e1010fracture in this cluster, with HRT being protective. This indicates
that risk factors for FF are different at different sites, and further-
more, affects the association of fracture between sites, since only
these factors were signiﬁcant for increased FF risk in this cluster.
An explanation for clustering of particular fracture sites, espe-
cially those listed above, may be the impact of speciﬁc areas of bone
loss, such as decreased femoral neck BMD, and areal vertebral BMD,
as suggested by one previous study in males [27]. Additionally, as
suggested above, fractures may occur at multiple sites during a
single fall, dependent on the mechanism of the fall. However, our
dataset does not specify the time at which fractures at each site
within an individual were sustained; therefore, we are unable to
further validate this hypothesis. Further investigations into clus-
tering of fracture sites will enable greater understanding of sites at
high risk of fracture in a given individual, thereby directing pre-
vention strategies.
5. Conclusions
This was a study on 6053 patients in a district hospital in North
West England, with a family history of FF, presenting for BMD
estimation. While this study conﬁrms previous results and risk
factors of FF in these patients, it adds to current data by predicting
the impact of various clinical factors on fractures at speciﬁc sites;
little data has previously been available on this. Furthermore, our
study demonstrates clustering of certain fractures within these
individuals, likely dependent on a certain proﬁle of speciﬁc risk
factors. Such data may be harnessed to aid fracture prophylaxis and
management strategies in patients with a history of FF, protecting
against bone loss and FF through mitigation of known risk factors.
All procedures performed in studies involving human partici-
pants were in accordance with the ethical standards of the insti-
tutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable
ethical standards.
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